Outcomes investigating the Absorb bioresorbable vascular scaffold (BVS) in patients undergoing percutaneous coronary intervention showed more adverse ischaemic events through 5 years compared with cobalt-chromium everolimus-eluting stents. However, the period of excess risk ended at 3 years.
In this short interview, Dr David Power (Mount Sinai Hospital, New York, US) discusses the final report from the ABSORB trial program, which was a large individual-patient-data pooled analysis to determine the safety and effectiveness of the Absorb BVS. The primary endpoints were target lesion failure and device thrombosis.
Interview Questions:
1. What is the reasoning behind the ABSORB trial?
2. What was the study design and patient population?
3. What are your key findings?
4. How can these findings be used to identify patients who would benefit most from the Absorb BVS?
5. What are the take-home messages for practice?
6. What further research is needed?
Recorded remotely from New York, 2025
Editors: Yazmin Sadik, Jordan Rance
Videographers: Dan Brent
Support: This is an independent interview produced by Radcliffe Vascular.
Comments